Get the Stockscreener App
13.70
1.15%
-0.16
After Hours:
13.43
-0.27
-1.97%
Contineum Therapeutics Inc stock is traded at $13.70, with a volume of 209.88K.
It is down -1.15% in the last 24 hours and up +10.39% over the past month.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
See More
Previous Close:
$13.86
Open:
$13.85
24h Volume:
209.88K
Relative Volume:
0.78
Market Cap:
$512.19M
Revenue:
$50.00M
Net Income/Loss:
$-59.98M
P/E Ratio:
-6.274
EPS:
-2.1836
Net Cash Flow:
$-55.54M
1W Performance:
+7.37%
1M Performance:
+10.39%
6M Performance:
+27.32%
1Y Performance:
+284.29%
1-Day Range:
$13.35
$14.04
1-Week Range:
$12.78
$14.95
52-Week Range:
$3.35
$16.33
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
13.70 | 518.18M | 50.00M | -59.98M | -55.54M | -2.1836 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
Contineum Therapeutics (CTNM) Declines 3.55%, Testing Key Support at $13.17Swing Trade Setups - Newser
Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? - Yahoo Finance Singapore
Contineum Therapeutics Inc. (CTNM) Q1 2026 Earnings: Clinical-Stage Biotech Reports Narrower Loss, Shares DipProduct Revenue Analysis - Newser
CTNM Q1 2026 Earnings: Narrower-than-Expected Loss Drives Strong EPS Surprise, but Shares SlipExpert Market Insights - Newser
Contineum Therapeutics, Inc.Common stock (CTNM) Stock Price, News, Quote & History - FinancialContent
CTNM Q1 2026 Earnings: Significant EPS Beat Amid Pipeline Progress, Stock Slightly DownViral Trade Signals - Newser
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential - Yahoo Finance
Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar - MSN
RA Capital affiliates report 1.296M shares of Contineum (CTNM) - Stock Titan
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance
Balyasny Group (CTNM) reports 2.42M shares via ADMF, ~7.40% stake - Stock Titan
Morgan Stanley Raises Price Target on Contineum Therapeutics to $16 From $14, Keeps Equalweight Rating - Moomoo
Contineum Therapeutics, Inc. Stock 12‑Month Price Target Raised to $22.33, Implies 58% Upside - TradingView
Morgan Stanley Maintains Contineum Therapeutics(CTNM.US) With Hold Rating, Raises Target Price to $16 - Moomoo
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference - BioSpace
Stream Contineum’s 2026 RBC Global Healthcare Conference talk live - Stock Titan
Ring Energy Announces Proposed Public Offering of Common Stock - Weekly Voice
TradingKey - TradingKey
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference - BioSpace
Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
RBC Capital Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet - MSN
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Entrada Therapeutics Inc (TRDA) and Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
CTNM SEC FilingsContineum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Contineum Therapeutics, Inc. Class A (CTNM) and Exelixis (EXEL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Contineum Therapeutics, Inc. Class A (CTNM) and Schrodinger (SDGR) - The Globe and Mail
Document - SEC.gov
Contineum Therapeutics, Inc. Q1 2026 Financial Report: Earnings, Clinical Pipeline Progress, and Forward-Looking Statements 14 - Minichart
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones - BioSpace
Contineum Therapeutics Sees Funding Sufficient Through Mid-2029 >CTNM - Moomoo
Contineum (NASDAQ: CTNM) Q1 loss narrows, cash reaches $246.3M - Stock Titan
Chronic pain data and cash runway to 2029 for Contineum (NASDAQ: CTNM) - Stock Titan
Contineum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Contineum Therapeutics (NASDAQ:CTNM) Shares Up 7.5%Time to Buy? - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Contineum Therapeutics CSO Daniel Lorrain sells $54,694 in stock - Investing.com
Contineum Therapeutics CSO Daniel Lorrain sells $54,694 in stock By Investing.com - Investing.com South Africa
Contineum (NASDAQ: CTNM) CSO trims stake under 10b5-1 plan - Stock Titan
CTNM (NASDAQ: CTNM) affiliate reports multiple 10b5-1 sales by Daniel Lorrain - Stock Titan
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Weekly Voice
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain - BioSpace
Contineum reports phase 1b trial results for chronic pain drug By Investing.com - Investing.com South Africa
Contineum Therapeutics Reports Positive Phase 1b Data for Chronic Pain Treatment - Moomoo
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):